Overview

* LivaNova ( LIVN ) Q3 revenue grows 12.5%, beating analyst expectations

* Adjusted EPS for Q3 beats consensus, reflecting strong operational performance

* Company raises 2025 revenue and EPS guidance, reflecting confidence in growth

Outlook

* LivaNova ( LIVN ) raises full-year 2025 revenue growth guidance to 8.5%-9.5% constant-currency

* Company expects 2025 adjusted EPS to be $3.80-$3.90

* LivaNova ( LIVN ) estimates 2025 adjusted free cash flow at $160 mln-$180 mln

Result Drivers

* CARDIOPULMONARY GROWTH - Revenue increased 18% driven by Essenz Perfusion System sales and strong consumables demand

* NEUROMODULATION GROWTH - Revenue rose 6.9% with growth across all regions

* OPERATING MARGIN EXPANSION - Driven by disciplined execution and enhanced productivity

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $357.80 $343.50

Revenue mln mln (7

Analysts

)

Q3 Beat $1.11 $0.91 (9

Adjusted Analysts

EPS )

Q3 EPS $0.49

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for LivaNova PLC ( LIVN ) is $60.50, about 10.8% above its November 4 closing price of $53.94

* The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)